Evidence map›Paper›PMID 25970632›Full record

ArticlePloS one2015

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.

Saleta Sierra, J Nikolai Dybowski, Alejandro Pironti, Dominik Heider, Lisa Güney, Alex Thielen, Stefan Reuter, Stefan Esser, Gerd Fätkenheuer, Thomas Lengauer and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Saleta SierraInstitute of Virology, University of Cologne, Cologne, Germany.
J Nikolai DybowskiDepartment for Bioinformatics, University of Duisburg-Essen, Essen, Germany.
Alejandro PirontiComputational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany.
Dominik HeiderDepartment for Bioinformatics, University of Duisburg-Essen, Essen, Germany.
Lisa GüneyInstitute of Virology, University of Cologne, Cologne, Germany.
Alex ThielenComputational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany.
Stefan ReuterDepartment of Gastroenterology, Hepatology and Infectiology, University Hospital of Düsseldorf, Düsseldorf, Germany.
Stefan EsserDepartment of Dermatology, University of Duisburg-Essen, Essen, Germany.
Gerd FätkenheuerFirst Department of Internal Medicine, University of Cologne, Cologne, Germany.
Thomas LengauerComputational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany.
Daniel HoffmannDepartment for Bioinformatics, University of Duisburg-Essen, Essen, Germany.
Herbert PfisterInstitute of Virology, University of Cologne, Cologne, Germany.
Björn JensenDepartment of Gastroenterology, Hepatology and Infectiology, University Hospital of Düsseldorf, Düsseldorf, Germany.
Rolf KaiserInstitute of Virology, University of Cologne, Cologne, Germany.
University of Cologne · DEUniversity of Duisburg-Essen · DEMax Planck Institute for Informatics · DEDüsseldorf University Hospital · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe analysed the impact of different parameters on genotypic tropism testing related to clinical outcome prediction in 108 patients on maraviroc (MVC) treatment.

methods87 RNA and 60 DNA samples were used. The viral tropism was predicted using the geno2pheno[coreceptor] and T-CUP tools with FPR cut-offs ranging from 1%-20%. Additionally, 27 RNA and 28 DNA samples were analysed in triplicate, 43 samples with the ESTA assay and 45 with next-generation sequencing. The influence of the genotypic susceptibility score (GSS) and 16 MVC-resistance mutations on clinical outcome was also studied.

resultsConcordance between single-amplification testing compared to ESTA and to NGS was in the order of 80%. Concordance with NGS was higher at lower FPR cut-offs. Detection of baseline R5 viruses in RNA and DNA samples by all methods significantly correlated with treatment success, even with FPR cut-offs of 3.75%-7.5%. Triple amplification did not improve the prediction value but reduced the number of patients eligible for MVC. No influence of the GSS or MVC-resistance mutations but adherence to treatment, on the clinical outcome was detected.

conclusionsProviral DNA is valid to select candidates for MVC treatment. FPR cut-offs of 5%-7.5% and single amplification from RNA or DNA would assure a safe administration of MVC without excluding many patients who could benefit from this drug. In addition, the new prediction system T-CUP produced reliable results.

Indexed as

AdolescentAdultAgedAged, 80 and overCyclohexanesFemaleGenes, ViralGenetic Association StudiesGenotypeHIV-1HIV Fusion InhibitorsHIV InfectionsHumansMaleMaravirocMiddle AgedCyclohexanesHIV Fusion InhibitorsMaravirocTriazoles

Identifiers

PMID25970632
PMCPMC4430318
OpenAlexW1579335790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.